FGF21 and metabolic dysfunction-associated steatotic liver disease: Animal studies using a FGF21 analog35 or overexpression of FGF2136, have demonstrated the ability to reverse obesity and related co-morbidities such as insulin resistance, adiposity and NAFLD.